Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Repare Therapeutics (Nasdaq: RPTX) announced a webcast presentation of data from its Phase 1 MYTHIC clinical trial on December 12, 2024. The trial evaluates the combination of lunresertib and camonsertib at the recommended Phase 2 dose in patients with platinum-resistant ovarian and endometrial cancers with specific genetic markers (CCNE1 amplification or FBXW7 or PPP2R1A mutations).
The presentation will feature Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center, alongside Repare's executive management team. The event will be accessible via conference call and live video webcast through the company's investor relations website.
Repare Therapeutics (Nasdaq: RPTX) ha annunciato una presentazione in webcast dei dati del suo studio clinico di Fase 1 MYTHIC il 12 dicembre 2024. Lo studio valuta la combinazione di lunresertib e camonsertib alla dose raccomandata per la Fase 2 in pazienti con tumori ovarici ed endometriali resistenti al platino che presentano specifici marcatori genetici (amplificazione di CCNE1 o mutazioni di FBXW7 o PPP2R1A).
La presentazione vedrà la partecipazione del Dr. Brian Slomovitz, Direttore di Oncologia Ginecologica al Mount Sinai Medical Center, insieme al team di gestione esecutiva di Repare. L'evento sarà accessibile tramite conferenza telefonica e webcast video in diretta attraverso il sito web delle relazioni con gli investitori dell'azienda.
Repare Therapeutics (Nasdaq: RPTX) anunció una presentación por webcast de datos de su ensayo clínico de Fase 1 MYTHIC el 12 de diciembre de 2024. El ensayo evalúa la combinación de lunresertib y camonsertib en la dosis recomendada de Fase 2 en pacientes con cánceres de ovario y endometrio resistentes al platino que presentan marcadores genéticos específicos (amplificación de CCNE1 o mutaciones de FBXW7 o PPP2R1A).
La presentación contará con el Dr. Brian Slomovitz, Director de Oncología Ginecológica en el Mount Sinai Medical Center, junto con el equipo de gestión ejecutiva de Repare. El evento será accesible a través de llamada de conferencia y webcast de video en vivo a través del sitio web de relaciones con los inversores de la empresa.
Repare Therapeutics (Nasdaq: RPTX)는 2024년 12월 12일 MYTHIC 임상 시험의 1상 데이터 발표를 웹캐스트 형식으로 진행한다고 발표했습니다. 이 시험은 특정 유전자 마커(CCNE1 증폭 또는 FBXW7 또는 PPP2R1A 변이)를 가진 백금 내성 난소 및 자궁내막암 환자에서 lunresertib와 camonsertib의 2상 권장 용량 조합을 평가합니다.
발표에는 Mount Sinai Medical Center의 부인과 종양학 이사인 Dr. Brian Slomovitz와 함께 Repare의 경영진 팀이 함께할 것입니다. 이 행사는 회사의 투자자 관계 웹사이트를 통해 전화 회의 및 실시간 비디오 웹캐스트로 접근할 수 있습니다.
Repare Therapeutics (Nasdaq: RPTX) a annoncé une présentation en webcast des données de son essai clinique de Phase 1 MYTHIC le 12 décembre 2024. Cet essai évalue la combinaison de lunresertib et camonsertib à la dose recommandée de Phase 2 chez des patients atteints de cancers des ovaires et de l'endomètre résistants au platine, présentant des marqueurs génétiques spécifiques (amplification de CCNE1 ou mutations de FBXW7 ou PPP2R1A).
La présentation sera animée par le Dr. Brian Slomovitz, Directeur de l'oncologie gynécologique au Mount Sinai Medical Center, aux côtés de l'équipe de direction de Repare. L'événement sera accessible via une conférence téléphonique et un webcast vidéo en direct sur le site web des relations investisseurs de l'entreprise.
Repare Therapeutics (Nasdaq: RPTX) kündigte eine Webcast-Präsentation von Daten aus seiner Phase-1-Studie MYTHIC am 12. Dezember 2024 an. Die Studie bewertet die Kombination von lunresertib und camonsertib in der empfohlenen Phase-2-Dosis bei Patienten mit platinresistenten Eierstock- und Endometriumkarzinomen mit spezifischen genetischen Markern (CCNE1-Amplifikation oder FBXW7- oder PPP2R1A-Mutationen).
Die Präsentation wird von Dr. Brian Slomovitz, Direktor für gynäkologische Onkologie am Mount Sinai Medical Center, sowie dem Führungsteam von Repare geleitet. Die Veranstaltung wird über Telefonkonferenz und Live-Video-Webcast über die Investor Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET
Conference Call and Webcast Details:
To access the call, please dial (646) 357-8785 (
About Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210360746/en/
Investor Relations & Media:
Robin Garner
Vice President and Head of Investor Relations
Repare Therapeutics Inc.
investor@reparerx.com
Source: Repare Therapeutics Inc.
FAQ
What is the purpose of Repare Therapeutics' MYTHIC clinical trial?
When will Repare Therapeutics (RPTX) present the MYTHIC trial data?
What type of cancers are being targeted in Repare Therapeutics' (RPTX) MYTHIC trial?
